Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 20, 2009Blood

Edoxaban in Patients Undergoing Total Hip Arthroplasty: A Phase IIb Dose-Finding Study.

View Full Paper
Ask AI
Bookmark
Share

Key result

Edoxaban 15 mg and 30 mg resulted in similar rates of thromboembolic events compared to enoxaparin (3.8% and 2.8% vs 4.1%) in patients undergoing total hip arthroplasty.

Why the study?

Does edoxaban prevent thromboembolic events in patients undergoing total hip arthroplasty compared to enoxaparin?

Population

n=264 patients undergoing total hip arthroplasty (THA) in Japan and Taiwan.

Comparison

Edoxaban 15 mg or 30 mg oral once daily, started… vs Enoxaparin 20 mg subcutaneous twice daily…

Design

RCT, Randomized, parallel group, Double-blind for edoxaban, open-label for…

Follow-up

11 to 14 days

Authors

TFTakashi FujiOsaka HospitalCWChen-Jen WangKaohsiung Chang Gung Memorial HospitalSFSatoru FujitaHosei University

Discussion

Loading...

Member takes

Implication

Edoxaban offers a convenient oral alternative to subcutaneous enoxaparin for VTE prophylaxis after hip arthroplasty; confirms comparable efficacy in this RCT.

Study Design

Type

RCT (n=264)

Blinding

Double-blind / Open-label

Randomization

Randomized

Multicenter

Yes

Structured PICO

Does edoxaban prevent thromboembolic events in patients undergoing total hip arthroplasty compared to enoxaparin?

P
Population
264 patients undergoing total hip arthroplasty in Japan and Taiwan, treated for 11 to 14 days.
I
Intervention
Edoxaban 15 mg or 30 mg oral once daily, started within 6 to 24 hours after surgery, administered for 11 to 14 days.
C
Comparator
Enoxaparin 20 mg subcutaneous twice daily (BID), started within 24 to 36 hours after surgery, administered for 11 to 14 days (open-label).
O
Outcome
Incidence of thromboembolic events (composite of asymptomatic deep vein thrombosis [DVT], symptomatic pulmonary embolism [PE], or symptomatic DVT) assessed by bilateral venography at the end of the study.composite

Main Result

Absolute Event Rate: 2.8% vs 4.1%

Oral edoxaban 15 mg and 30 mg once daily demonstrated comparable efficacy and safety to subcutaneous enoxaparin for the prevention of thromboembolic events following total hip arthroplasty.

Cite This Study

Fuji et al. (2009) conducted an RCT in Total hip arthroplasty (THA) (n=264). Edoxaban vs. Enoxaparin 20 mg BID was evaluated on Incidence of thromboembolic events (composite of asymptomatic deep vein thrombosis [DVT], symptomatic pulmonary embolism [PE], or symptomatic DVT). Edoxaban 15 mg and 30 mg resulted in similar rates of thromboembolic events compared to enoxaparin (3.8% and 2.8% vs 4.1%) in patients undergoing total hip arthroplasty.

synapsesocial.com/papers/6a9d95dec53a4841f7680140https://doi.org/10.1182/blood.v114.22.2098.2098
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety of Edoxaban Versus Enoxaparin for the Prevention of Venous Thromboembolism Following Total Hip Arthroplasty: STARS J-V trial2010 · 46 citations
  2. 2Edoxaban Versus Enoxaparin for the Prevention of Venous Thromboembolism: Pooled Analysis of Venous Thromboembolism and Bleeding From STARS E-3 and STARS J-V2011 · 19 citations
  3. 3Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, for Thromboprophylaxis After Total Hip Arthroplasty in Japan and Taiwan2014 · 57 citations
  4. 4Safety and efficacy of edoxaban in patients undergoing hip fracture surgery2014 · 104 citations
  5. 5Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials2016 · 13 citations